Why Vertex (VERX) Might be Well Poised for a Surge
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
MarketWatch14h
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity
Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...
Business Insider1d
Vertex price target raised to $62 from $50 at Morgan Stanley
Morgan Stanley analyst Chris Quintero raised the firm’s price target on Vertex (VERX) to $62 from $50 and keeps an Overweight rating on the shares. The firm has greater conviction in Vertex being a ...
Vertex’s Growth Potential and Raised Price Target Amidst ERP Supercycle and E-Invoicing Expansion
Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...
Zacks.com on MSN5d
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Barchart on MSN6d
1 Penny Stock to Grab Now for 183% Upside Potential
Editas Medicine Inc. (EDIT) is a clinical-stage biotechnology company involved in developing genome treatments for rare ...